Literature DB >> 26494426

The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans.

Jacqueline Deen1, Lorenz von Seidlein2, Francisco J Luquero3, Christopher Troeger4, Rita Reyburn5, Anna Lena Lopez6, Amanda Debes7, David A Sack7.   

Abstract

Oral cholera vaccination could be deployed in a diverse range of situations from cholera-endemic areas and locations of humanitarian crises, but no clear consensus exists. The supply of licensed, WHO-prequalified cholera vaccines is not sufficient to meet endemic and epidemic needs worldwide and so prioritisation is needed. We have developed a scenario approach to systematically classify situations in which oral cholera vaccination might be useful. Our scenario approach distinguishes between five types of cholera epidemiology based on experiences from around the world and provides evidence that we hope will spur the development of detailed guidelines on how and where oral cholera vaccines could, and should, be most rationally deployed.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26494426     DOI: 10.1016/S1473-3099(15)00298-4

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  3 in total

1.  Model distinguishability and inference robustness in mechanisms of cholera transmission and loss of immunity.

Authors:  Elizabeth C Lee; Michael R Kelly; Brad M Ochocki; Segun M Akinwumi; Karen E S Hamre; Joseph H Tien; Marisa C Eisenberg
Journal:  J Theor Biol       Date:  2017-01-24       Impact factor: 2.691

2.  Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model.

Authors:  Eun Young Lee; Sena Lee; Semi Rho; Jae-Ouk Kim; Seuk Keun Choi; Young Jin Lee; Joo Young Park; Manki Song; Jae Seung Yang
Journal:  Clin Exp Vaccine Res       Date:  2018-07-31

3.  The opportunities & challenges in delivering oral cholera vaccines.

Authors:  Jacqueline Deen; David A Sack
Journal:  Indian J Med Res       Date:  2016-08       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.